文献速递胃肠外科围术期管理与 ERAS

单吻合口袖状回肠旁路术(SASI)的疗效与并发症:单臂meta分析

Single anastomosis sleeve ileal (SASI) bypass outcomes and complications: single-arm meta-analysis.
PubMed 文献 · Surg Endosc · 2025-12-01

该单臂meta分析系统检索4个数据库,纳入38项研究、最多2555例患者,评估SASI旁路的疗效与安全性。结果显示6、12、24个月EWL%分别为63.07%、82.44%、93.21%,糖尿病、高血压、血脂异常、GERD和OSA缓解率均较高,总体并发症率13.70%,无死亡报告。

要点

  • SASI旁路术后12个月EWL%达82.44%,24个月达93.21%
  • 糖尿病缓解率92.67%,高血压79.06%,血脂异常82.64%
  • 总体并发症率13.70%,严重并发症(Clavien-Dindo III-IV级)5.18%,无死亡

核心结论

  • SASI旁路是一种高效的代谢与减重手术,可实现显著减重并对多种肥胖相关疾病有高缓解率。
  • SASI可能使BMI较高且合并多种肥胖相关疾病的患者获益。
  • 多数并发症为轻度,严重并发症不常见,但仍需进一步比较研究确立其相对于其他减重技术的优势。

研究设计与样本

  • 系统综述与单臂meta分析,检索PubMed、Scopus、Embase和Cochrane数据库。
  • 初检387篇文章,最终纳入38项研究,最多贡献2555例患者数据。
  • 随访时间范围为6至60个月。

主要发现

  • 汇总EWL%在6个月为63.07%,12个月为82.44%,24个月为93.21%。
  • 糖尿病缓解率92.67%,高血压79.06%,血脂异常82.64%,GERD 81.63%,OSA 81.04%。
  • 采用Clavien-Dindo分级,总体平均并发症率13.70%,轻度(I-II级)7.74%,严重(III-IV级)平均5.18%。
  • 未报告死亡病例。

关键数值与推荐

  • 减重效果:EWL% 6个月63.07%、12个月82.44%、24个月93.21%。
  • 肥胖相关疾病缓解率:糖尿病92.67%、高血压79.06%、血脂异常82.64%、GERD 81.63%、OSA 81.04%。
  • 并发症:总体平均13.70%,Clavien-Dindo I-II级7.74%,III-IV级平均5.18%,无死亡。

临床怎么用

  • 可将SASI旁路作为BMI较高且合并多种肥胖相关疾病患者的减重代谢手术选项之一。
  • 术前应向患者说明多数并发症为轻度、严重并发症不常见且无死亡报告,但需个体化评估。
  • 术后随访应关注减重效果及糖尿病、高血压、血脂异常、GERD和OSA的缓解情况。

局限性

  • 单臂meta分析缺乏对照组,无法直接比较SASI与其他减重技术的优劣。
  • 原文指出需要进一步比较研究来确立SASI相对于其他减重技术的优势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Single Anastomosis Sleeve Ileal (SASI) bypass combines sleeve gastrectomy with a single anastomosis to the ileum, preserving digestive continuity to reduce deficiencies while treating obesity-related conditions. METHODS: This study systematically reviewed SASI bypass outcomes and conducted a single-arm meta-analysis to assess its efficacy and safety. A comprehensive literature search across PubMed, Scopus, Embase, and Cochrane databases initially identified 387 articles, with 38 studies meeting inclusion criteria, contributing data on a maximum of 2,555 patients. Follow-up ranged from 6 to 60 months. RESULTS: Meta-analysis showed significant weight loss, with pooled Excess Weight Loss Percentage (EWL%) of 63.07% at 6 months, 82.44% at 12 months, and 93.21% at 24 months. The procedure demonstrated high remission rates for obesity-related conditions, including diabetes (92.67%), hypertension (79.06%), dyslipidemia (82.64%), gastroesophageal reflux disease (GERD) (81.63%), and obstructive sleep apnea (OSA) (81.04%). Postoperative complications were classified using the Clavien-Dindo grading system, with an overall mean complication rate of 13.70%. Mild complications (Grades I-II) accounted for 7.74%, while severe complications (Grades III-IV) had a mean rate of 5.18%. No deaths were reported. CONCLUSIONS: These findings suggest SASI bypass is a highly effective metabolic and bariatric procedure, achieving substantial weight loss and high remission rates for multiple obesity-related conditions. Given its efficacy, SASI may benefit patients with higher body mass index (BMI) and multiple obesity-associated medical conditions. While most complications are mild and severe ones infrequent, further comparative studies are needed to establish its advantages over other bariatric techniques.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Rodrigues de Oliveira Filho J, Bregion PB, Juca RH, et al. Single anastomosis sleeve ileal (SASI) bypass outcomes and complications: single-arm meta-analysis. Surg Endosc. 2025. PMID: 41326728. doi:10.1007/s00464-025-12421-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。